Lev Fertelmeyster

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Iridias breakthrough molecular identity technology combines cybersecurity, blockchain, molecular science, robotics, and AI to create an immutable foundation of truth in global commerce. Were not just securing supply chains, were establishing a new bedrock of trust that will reshape how humanity conducts trade, protects innovation, and builds economic relationships. Our technology ensures the authenticity of critical materials, assets and products that power the global economy, setting new standards for transparency and security across industries.

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Iridias breakthrough molecular identity technology combines cybersecurity, blockchain, molecular science, robotics, and AI to create an immutable foundation of truth in global commerce. Were not just securing supply chains, were establishing a new bedrock of trust that will reshape how humanity conducts trade, protects innovation, and builds economic relationships. Our technology ensures the authenticity of critical materials, assets and products that power the global economy, setting new standards for transparency and security across industries.